Increases urinary HMGA1 in serous epithelial ovarian cancer patients.

Zhou J, Xie M, He H, Shi Y, Luo B, Gong G, Li J, Wang J, Wu X, Wen J
Cancer biomarkers : section A of Disease markers · 2015 · doi:10.3233/cbm-150457 · PMID:25586095 · PMC12964676
OA: closed
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-14 · read from full text ⓘ

This study investigated whether urinary high mobility group A1 (HMGA1) levels could serve as a noninvasive diagnostic biomarker for serous epithelial ovarian cancer. Researchers compared urine and serum samples from healthy controls, patients with benign gynecological conditions, and individuals with varying grades of ovarian cancer using enzyme-linked immunosorbent assays. The results demonstrated that urinary HMGA1 was significantly elevated in cancer patients, particularly those with grade 3 tumors, and showed superior sensitivity and specificity compared to serum CA-125 levels when analyzed via ROC curves. Relevance to endometriosis: The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BackgroundSerous epithelial ovarian cancer is the most common variety of ovarian cancer and is currently diagnosed using serum CA-125 levels. HMGA1 a small 10.6-12 kDa protein, has been implicated as a potentially important tumor biomarker and may enter the urinary trace, thus potentially able to serve as a disease biomarker.ObjectiveTo determine if urine HMGA1 can be detected and potentially serve as a clinical diagnostic biomarkers.MethodUrine was collected from 20 healthy normal control patients, 20 patients with benign gynecological disease and 55 epithelial ovarian specimens of which 20 exhibited G1/2 ovarian cancer and 35 G3 ovarian cancers. Serum was also collected from 20 healthy normal control patients and 55 serous epithelial ovarian cancers patients. HMGA1 levels were examined via enzyme-linked immunosorbent assay (ELISA) and were reported independently and normalized to urine creatinine levels. Serum CA-125 levels were examined via enzyme assay and the data was analyzed via box and ROC analysis.ResultsUrine HMGA1 was significantly elevated in serous epithelial ovarian cancer specimen relative to healthy control specimens with G3 specimens exhibiting higher levels than G1-G2 specimens. ROC analysis revealed a high degree of sensitivity and specificity for urine HMGA1 detection in ovarian cancer, with a higher AUC value noted for urine HMGA1 than serum CA-125. Furthermore, urine HMGA1 and serum CA-125 combined AUC indicated that urine HMGA1 is an excellent diagnostic biomarker for serous epithelial ovarian cancer.ConclusionOur data indicates that measuring urine HMGA1 may serve as a useful diagnostic tool.
Full text 1,814 characters · extracted from oa-html · 6 sections · click to expand

Abstract

BACKGROUND: Serous epithelial ovarian cancer is the most common variety of ovarian cancer and is currently diagnosed using serum CA-125 levels. HMGA1 a small 10.6-12 kDa protein, has been implicated as a potentially important tumor biomarker and may enter the urinary trace, thus potentially able to serve as a disease biomarker.

Objective

To determine if urine HMGA1 can be detected and potentially serve as a clinical diagnostic biomarkers.

Method

Urine was collected from 20 healthy normal control patients, 20 patients with benign gynecological disease and 55 epithelial ovarian specimens of which 20 exhibited G1/2 ovarian cancer and 35 G3 ovarian cancers. Serum was also collected from 20 healthy normal control patients and 55 serous epithelial ovarian cancers patients. HMGA1 levels were examined via enzyme-linked immunosorbent assay (ELISA) and were reported independently and normalized to urine creatinine levels. Serum CA-125 levels were examined via enzyme assay and the data was analyzed via box and ROC analysis.

Results

Urine HMGA1 was significantly elevated in serous epithelial ovarian cancer specimen relative to healthy control specimens with G3 specimens exhibiting higher levels than G1-G2 specimens. ROC analysis revealed a high degree of sensitivity and specificity for urine HMGA1 detection in ovarian cancer, with a higher AUC value noted for urine HMGA1 than serum CA-125. Furthermore, urine HMGA1 and serum CA-125 combined AUC indicated that urine HMGA1 is an excellent diagnostic biomarker for serous epithelial ovarian cancer.

Conclusion

Our data indicates that measuring urine HMGA1 may serve as a useful diagnostic tool.

Keywords

HMGA1, urine, biomarker, epithelial ovarian cancer, noninvasive Full Text The Full Text of this article is available as a PDF (262.4 KB).

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-16T09:21:09.727480+00:00
unpaywall
last seen: 2026-08-21T06:37:11.537704+00:00